Walk into a clinic in Boston on a Tuesday morning. A young adult with cystic fibrosis is about to inhale a mist that, until recently, did not exist in any meaningful form. The mist contains lipid nanoparticles. The nanoparticles contain mRNA. The mRNA contains the instructions for a working copy of CFTR - the protein their genome has been failing to make since birth. This is RCT2100. It is the first inhaled mRNA therapy of its kind in human trials. The biotech behind it is called ReCode Therapeutics, and the strange thing about ReCode is that everyone in the field already knew this should be possible. ReCode just did it.
The company is 61 people. Half are in Menlo Park, the rest in Dallas. The lobby is unremarkable. The science is not.
01 / The ProblemThe lung had a delivery problem
Genetic medicine has a dirty little secret, which is that nearly all of it ends up in the liver. The liver is hungry, vascular, and accepting of strangers. A lipid nanoparticle injected into a bloodstream drifts there by default. For diseases of the liver - certain genetic deficiencies, transthyretin amyloidosis - this is excellent news. For diseases of the lung, it is a brick wall.
Cystic fibrosis lives in the lung. So does primary ciliary dyskinesia. So do most of the rare respiratory diseases that pharmaceutical companies politely ignored for thirty years. Vertex's modulator drugs solved the problem for roughly nine out of ten CF patients, which was both a miracle and a sentence: the tenth patient, the one whose mutation cannot be coaxed by a small molecule, was left to wait. They have been waiting.
The liver gets everything. Every gene therapy. Every LNP. Every party invitation. You can imagine how the lung feels about this.
- the central tension, more or lessThe delivery problem was not a footnote. It was the whole story. You could engineer the most elegant mRNA payload in the world and it would land, like every other LNP, in the liver. The cargo was solved. The address was not.
02 / The BetWhat the founders saw, that nobody else did
In 2015, a chemist at UT Southwestern named Daniel Siegwart began publishing on something he called Selective Organ Targeting - SORT. The trick was almost embarrassingly simple to describe: add a fifth, charged lipid to the standard four-component LNP recipe, and you could steer the particle to a chosen organ. Lung. Spleen. Bone marrow. The recipe became the platform. The platform became a company.
The original ReCode came out of Dallas in 2015. In 2020 it merged with TranscripTx, a California outfit run by David Lockhart, Leon Chen, and Peter Thompson. The combined entity took ReCode's delivery science and TranscripTx's respiratory clinical thinking and pointed both at cystic fibrosis. It was a tidy little bet: the platform would prove out in the toughest pulmonary indication; everything else would follow.
To advise them, the company assembled a Scientific Advisory Board that included Katalin Kariko - the biochemist whose pseudouridine work made mRNA vaccines possible and who later won a Nobel Prize for it. If you are going to bet on inhaled mRNA, you may as well do it with the person who arguably invented the cargo.
You don't hire a Nobel laureate onto your SAB because it looks good in a slide deck. You hire one because the question is hard enough to need her.
- the math of credibility03 / The ProductSORT LNP, and the things it carries
The platform is the moat. Anyone can synthesize mRNA. Few can deliver it where it is needed. ReCode's SORT LNP is modular - swap the targeting lipid and the same chassis goes to a different tissue. Reload the cargo, and the same delivery vehicle carries something new: messenger RNA, guide RNA, a CRISPR base editor, a gene-correction payload. The same truck. Different addresses. Different freight.
The pipeline, briefly
RCT2100 is the lead asset: an inhaled mist that delivers CFTR mRNA to the airway cells of cystic fibrosis patients who fall outside the reach of existing modulators. Phase 1 healthy-volunteer dosing began. Phase 1b patient dosing followed. The FDA granted Orphan Drug Designation.
RCT1100 targets primary ciliary dyskinesia, a rare disease that gives patients faulty cilia, chronic infections, and no approved disease-modifying therapy whatsoever. RCT1100 delivers DNAI1 mRNA, also via inhalation.
A third program, run jointly with Intellia Therapeutics and supported by the Cystic Fibrosis Foundation, swaps the cargo entirely. Instead of teaching the cell to translate a working CFTR, it edits the gene that codes for the broken one. SORT LNP is the delivery truck. CRISPR is the cargo. Same truck, different freight.
Company milestones
04 / The ProofWhere the receipts live
The argument for a clinical-stage biotech is, in the end, the argument for its receipts. Three matter here.
First, the regulators. The FDA granted RCT2100 Orphan Drug Designation. The agency does not give that title to vapor.
Second, the patients. Phase 1b patient dosing for RCT2100 is, simply, the thing the field thought might be a decade away. ReCode delivered it in the back half of the 2020s. There are humans inhaling functional CFTR mRNA right now.
Third, the money. Money is the dullest proof, but it is honest. Investors who write checks of this size do due diligence that no press release will ever describe.
Capital raised, by round
Bayer, Pfizer, Sanofi, MPM, EcoR1, Vida, and the Cystic Fibrosis Foundation walk into a cap table. There is no punchline. They all stayed.
- the syndicate, summarized05 / The MissionBeyond the liver, beyond the lung
The official mission is to deliver the promise of genetic medicines to patients with serious diseases. The real mission, when you parse the science, is broader: to make the LNP a programmable vehicle for any cargo, headed to any organ. The lung is the proving ground. After that comes the rest of the body.
If SORT LNP holds, a generation of genetic medicines that were impossible because of delivery become merely difficult because of biology. That is a useful kind of difficult. It is the kind that gets solved.
Who this helps
The roughly ten percent of cystic fibrosis patients whose mutations do not respond to existing modulators. People living with primary ciliary dyskinesia who currently have no approved disease-modifying therapy. And eventually, in the optimist's version of the next decade, patients with any genetic disease whose target tissue is not the liver.
06 / TomorrowWhy this matters past 2030
The COVID vaccines proved that mRNA could become a real medicine. They also revealed how narrow our delivery toolkit was. Every leading mRNA program after 2020 ran into the same wall: the liver gets everything. ReCode is among the few clinical-stage companies for whom that sentence is no longer true.
If RCT2100 reads out positively, the second-order effects ripple. Inhaled mRNA becomes plausible across pulmonary disease. SORT LNP becomes a partnering platform for pharma companies who suddenly need to reach tissues their own delivery systems cannot. The 10% of cystic fibrosis patients waiting at the edge of the modulator era have a different conversation with their pulmonologist. The lung, finally, gets a party invitation.
Back in that clinic in Boston, the patient breathes in. The mist enters the airway. The lipid nanoparticles, engineered specifically to find lung cells and not the liver, do exactly that. The mRNA they carry is read by the ribosome. The ribosome makes CFTR - the protein the patient's genome could not. For the duration of that dose, in those cells, the cystic fibrosis is, in a measurable molecular sense, not happening. This is the thing ReCode built. The liver, for once, is not invited.